Kyverna Therapeutics (KYTX) Enterprise Value (2023 - 2026)
Kyverna Therapeutics posted quarterly Enterprise Value of -$233.0 million for Q1 2026, up 4.0% year-on-year from -$224.0 million in Q1 2025, and up 16.58% on a QoQ basis from -$279.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Enterprise Value data on file, last reported at -$233.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 4.0% year-over-year to -$233.0 million; the trailing twelve-month figure through Mar 2026 stood at -$233.0 million (up 4.0% YoY), and the FY2025 full-year result was -$279.3 million, up 2.35% from the prior year.
- Enterprise Value for Q1 2026 stood at -$233.0 million, up from -$279.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$23.0 million in Q3 2023 and bottomed at -$369.8 million in Q1 2024.
- The 4-year median for Enterprise Value is -$233.0 million (2026), against an average of -$202.6 million.
- The widest annual swing landed in 2024, when Enterprise Value slumped 1300.21%; it then surged 46.78% in 2025.
- A 4-year view of Enterprise Value shows it stood at -$57.5 million in 2023, then tumbled by 396.98% to -$286.0 million in 2024, then gained by 2.35% to -$279.3 million in 2025, then gained by 16.58% to -$233.0 million in 2026.
- The last three Enterprise Value figures came in at -$233.0 million (Q1 2026), -$279.3 million (Q4 2025), and -$171.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -232.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -232.95 Mn |
| Dec 31, 2025 | -279.25 Mn |
| Sep 30, 2025 | -171.16 Mn |
| Jun 30, 2025 | -210.34 Mn |
| Mar 31, 2025 | -242.65 Mn |
| Dec 31, 2024 | -285.98 Mn |
| Sep 30, 2024 | -321.59 Mn |
| Jun 30, 2024 | -346.24 Mn |
| Mar 31, 2024 | -369.79 Mn |
| Dec 31, 2023 | -57.54 Mn |
| Sep 30, 2023 | -22.97 Mn |
| Jun 30, 2023 | -53.43 Mn |
| Mar 31, 2023 | -39.79 Mn |